COVID-19 SARS-CoV-2 preprints from medRxiv and bioRxiv

31,536 Articles (22,881 medRxiv, 8,655 bioRxiv)

Most recent first Previous |  Page 1044: Articles 10431-10440  | Next

An elite broadly neutralizing antibody protects SARS-CoV-2 Omicron variant challenge
Zhou, B., Zhou, R., Chan, J. F.-W., Luo, M., Peng, Q., Yuan, S., Mok, B. W.-Y., Chen, B., Wang, P., Poon, V. K.-M., Chu, H., Chan, C. C.-S., Tsang, J. O.-L., Chan, C. C.-Y., Au, K.-K., Man, H.-O., Lu, L., To, K. K.-W., Chen, H., Yuen, K.-Y., Chen, Z.
10.1101/2022.01.05.475037 — Posted: 2022-01-05
Performance evaluation of novel fluorescent-based lateral immune flow assay (LIFA) for rapid detection and quantitation of total anti-SARS-CoV-2 S-RBD binding antibodies in infected individuals
Shurrab, F. M., Younes, N., Al-Sadeq, D. W., Qotba, H., Abu-Raddad, L. J., Nasrallah, G.
10.1101/2022.01.04.22268717 — Posted: 2022-01-05
COVID-19 vaccination status is associated with physical activity in German-speaking countries: the COR-PHYS-Q cohort study
Schwendinger, F., Boeck, H. T., Infanger, D., Faulhaber, M., Tegtbur, U., Schmidt-Trucksäss, A.
10.1101/2022.01.01.21268576 — Posted: 2022-01-05
Reported Cases of Multisystem Inflammatory Syndrome in Children Aged 12 to 20 Years in the United States Who Received COVID-19 Vaccine, December 2020 through August 2021
Yousaf, A. R., Cortese, M., Taylor, A. W., Broder, K. R., Oster, M. E., Wong, J. M., Guh, A. Y., McCormick, D. W., Kamidani, S., Schlaudecker, E., Edwards, K., Creech, C. B., Staat, M. A., Belay, E. D., Marquez, P., Su, J. R., Salzman, M. B., Thompson, D., Campbell, A. P., MIS-C Investigation Authorship Group
10.1101/2022.01.03.22268681 — Posted: 2022-01-05
Immune responses to inactivated and vector-based vaccines in individuals previously infected with SARS-CoV-2
Suntronwong, N., Yorsaeng, R., Auphimai, C., Thongmee, T., Vichaiwattana, P., Kanokudom, S., Assawakosri, S., Nilyanimit, P., Srimuan, D., Thatsanatorn, T., Sudhinaraset, N., Wanlapakorn, N., Poovorawan, Y.
10.1101/2022.01.03.22268704 — Posted: 2022-01-05
Burden of SARS-CoV-2 and protection from symptomatic second infection in children
Kubale, J. T., Balmaseda, A., Frutos, A. M., Sanchez, N., Plazaola, M., Ojeda, S., Saborio, S., Lopez, R., Barilla, C., Vasquez, G., Moreira, H., Gajewski, A., Campredon, L., Maier, H., Chowdhury, M., Cerpas, C., Harris, E., Kuan, G., Gordon, A.
10.1101/2022.01.03.22268684 — Posted: 2022-01-05
Should rapid antigen tests be government funded in Australia? An economic evaluation
Karnon, J., Afzali, H., Bonevski, B.
10.1101/2022.01.03.22268709 — Posted: 2022-01-05
Seroresponse to third doses of SARS-CoV-2 vaccine among patients receiving maintenance dialysis
Hsu, C. M., Lacson, E. K., Manley, H. J., Aweh, G. N., Miskulin, D., Johnson, D., Weiner, D. E.
10.1101/2022.01.03.21268549 — Posted: 2022-01-05
The French domestic "sanitary pass" did not solve Covid-19 vaccination inequities in France
Debarre, F., Lecoeur, E., Guimier, L., Jauffret-Roustide, M., Jannot, A.-S.
10.1101/2022.01.03.22268676 — Posted: 2022-01-05
Full title: COVID-19 disease progression according to initial symptoms. A telemedicine cohort study.
Murillo-Villanueva, K., Velazquez-Hernandez, B., Jacome-Mondragon, J. A., Cervantes-Llamas, J. J., Talavera, J. O.
10.1101/2022.01.03.22268669 — Posted: 2022-01-05

RSS  Collection RSS | JSON

The feeds linked above output metadata for the 100 most recent papers in the collection.To access the metadata for the entire collection in JSON or XML, visit the collection API.

Subject Areas
* The Clinical Trials and Epidemiology subject categories are now closed to new submissions following the completion of bioRxiv's clinical research pilot project and launch of the dedicated health sciences server medRxiv (submit.medrxiv.org). New papers that report results of Clinical Trials must now be submitted to medRxiv. Most new Epidemiology papers also should be submitted to medRxiv, but if a paper contains no health-related information, authors may choose to submit it to another bioRxiv subject category (e.g., Genetics or Microbiology).